医薬品の副作用調査の世界市場分析:臨床試験フェーズ別(前臨床試験、フェーズI / 1、フェーズII / 2、フェーズIII / 3、フェーズIV / 4試験)、サービス提供者別(自宅内、契約委託)、セグメント予測、-2020...市場調査レポートについてご紹介

【英文タイトル】Pharmacovigilance Market Analysis By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial), By Type Of Service Providers (In House, Contract Outsourcing) And Segment Forecasts To 2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents

Chapter 1. Executive Summary
1.1. Pharmacovigilance– Industry Summary and Critical Success Factors (CSFs)
Chapter 2. Pharmacovigilance Industry Outlook
2.1. Market Segmentation
2.2. Market Size and Growth Prospects
2.3. Pharmacovigilance – Market dynamics
2.3.1. Market Driver Analysis
2.3.2. Market Restraint Analysis
2.4. Key Opportunities Prioritized
2.5. Pharmacovigilance – PESTEL Analysis
2.6. Pharmacovigilance Company Market Share Analysis, 2013
Chapter 3. Pharmacovigilance Clinical Trial Phase Outlook
3.1. Pharmacovigilance market share, by clinical trial phase, 2013 & 2020
3.2. Preclinical
3.2.1. Preclinical Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.3. Phase 0
3.3.1. Phase 0 Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.4. Phase I
3.4.1. Phase I Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.5. Phase II
3.5.1. Phase II Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.6. Phase III
3.6.1. Phase III Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.7. Phase IV
3.7.1. Phase IV Market Estimates and Forecasts, 2012 – 2020 (USD Million)
Chapter 4. Pharmacovigilance Type of Service Provider Outlook
4.1. Pharmacovigilance market share, by type of service provider, 2013 & 2020
4.2. In- House
4.2.1. In-House Market Estimates and Forecasts, 2012 – 2020 (USD Million)
4.3. Contract Outsourcing
4.3.1. Contract Outsourcing Market Estimates and Forecasts, 2012 – 2020 (USD Million)
Chapter 5. Pharmacovigilance Regional Outlook
5.1. Pharmacovigilance market share by region, 2012 & 2020
5.2. North America
5.2.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.2.2. Market Estimates and Forecasts, by Type of Service Provider
5.3. Europe
5.3.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.3.2. Market Estimates and Forecasts, by Type of Service Provider
5.4. Asia Pacific
5.4.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.4.2. Market Estimates and Forecasts, by Type of Service Provider
5.5. RoW
5.5.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.5.2. Market Estimates and Forecasts, by Type of Service Provider
Chapter 6. Competitive Landscape
6.1 Accenture Plc.
6.1.1 Company Overview
6.1.2 Financial Performance
6.1.3 Product Benchmarking
6.1.4 Strategic Initiatives
6.2 Boehringer Ingelheim GmbH
6.2.1 Company Overview
6.2.2 Financial Performance
6.2.3 Product Benchmarking
6.2.4 Strategic Initiatives
6.3 Bristol-Myers Squibb
6.3.1 Company Overview
6.3.2 Financial Performance
6.3.3 Product Benchmarking
6.3.4 Strategic Initiatives
6.4 Clinquest Group B.V.
6.4.1 Company Overview
6.4.2 Financial Performance
6.4.3 Product Benchmarking
6.4.4 Strategic Initiatives
6.5 Cognizant Technology Solutions Corporation
6.5.1 Company Overview
6.5.2 Financial Performance
6.5.3 Product Benchmarking
6.5.4 Strategic Initiatives
6.6 Covance, Inc.
6.6.1 Company Overview
6.6.2 Financial Performance
6.6.3 Product Benchmarking
6.6.4 Strategic Initiatives
6.7 F. Hoffmann-La Roche Ltd
6.7.1 Company Overview
6.7.2 Financial Performance
6.7.3 Product Benchmarking
6.7.4 Strategic Initiatives
6.8 GlaxoSmithKline (GSK)
6.8.1 Company Overview
6.8.2 Financial Performance
6.8.3 Product Benchmarking
6.8.4 Strategic Initiatives
6.9 IBM Corporation
6.9.1 Company Overview
6.9.2 Financial Performance
6.9.3 Product Benchmarking
6.9.4 Strategic Initiatives
6.10 ICON, Plc
6.10.1 Company Overview
6.10.2 Financial Performance
6.10.3 Product Benchmarking
6.10.4 Strategic Initiatives
6.11 iGATE Corporation
6.11.1 Company Overview
6.11.2 Financial Performance
6.11.3 Product Benchmarking
6.11.4 Strategic Initiatives
6.12 iMEDGlobal Corporation
6.12.1 Company Overview
6.12.2 Financial Performance
6.12.3 Product Benchmarking
6.12.4 Strategic Initiatives
6.13 Infosys
6.13.1 Company Overview
6.13.2 Financial Performance
6.13.3 Product Benchmarking
6.13.4 Strategic Initiatives
6.14 Ipca Laboratories Ltd
6.14.1 Company Overview
6.14.2 Financial Performance
6.14.3 Product Benchmarking
6.14.4 Strategic Initiatives
6.15 Janssen Research & Development, LLC
6.15.1 Company Overview
6.15.2 Financial Performance
6.15.3 Product Benchmarking
6.15.4 Strategic Initiatives
6.16 Novartis International AG
6.16.1 Company Overview
6.16.2 Financial Performance
6.16.3 Product Benchmarking
6.16.4 Strategic Initiatives
6.17 PAREXEL International Corporation
6.17.1 Company Overview
6.17.2 Financial Performance
6.17.3 Product Benchmarking
6.17.4 Strategic Initiatives
6.18 Pfizer, Inc.
6.18.1 Company Overview
6.18.2 Financial Performance
6.18.3 Product Benchmarking
6.18.4 Strategic Initiatives
6.19 Pharmaceutical Product Development, Inc. (PPD, Inc.)
6.19.1 Company Overview
6.19.2 Financial Performance
6.19.3 Product Benchmarking
6.19.4 Strategic Initiatives
6.20 Sanofi Aventis
6.20.1 Company Overview
6.20.2 Financial Performance
6.20.3 Product Benchmarking
6.20.4 Strategic Initiatives
6.21 Synowlwedge LLC
6.21.1 Company Overview
6.21.2 Financial Performance
6.21.3 Product Benchmarking
6.21.4 Strategic Initiatives
6.22 Wipro Ltd.
6.22.1 Company Overview
6.22.2 Financial Performance
6.22.3 Product Benchmarking
6.22.4 Strategic Initiatives
6.23 PRA Health Sciences Inc.
6.23.1 Company Overview
6.23.2 Financial Performance
6.23.3 Product Benchmarking
6.23.4 Strategic Initiatives
6.24 Quantum Solutions India
6.24.1 Company Overview
6.24.2 Financial Performance
6.24.3 Product Benchmarking
6.24.4 Strategic Initiatives
6.25 Quintiles Transnational Corporation
6.25.1 Company Overview
6.25.2 Financial Performance
6.25.3 Product Benchmarking
6.25.4 Strategic Initiatives
6.26 inVentiv Health Inc.
6.26.1 Company Overview
6.26.2 Financial Performance
6.26.3 Product Benchmarking
6.26.4 Strategic Initiatives
6.27 OptumInsight, Inc.
6.27.1 Company Overview
6.27.2 Financial Performance
6.27.3 Product Benchmarking
6.27.4 Strategic Initiatives
6.28 United BioSource Corporation
6.28.1 Company Overview
6.28.2 Financial Performance
6.28.3 Product Benchmarking
6.28.4 Strategic Initiatives
6.29 Ecron Acunova
6.29.1 Company Overview
6.29.2 Financial Performance
6.29.3 Product Benchmarking
6.29.4 Strategic Initiatives
6.30 Fortitude Clinical
6.30.1 Company Overview
6.30.2 Financial Performance
6.30.3 Product Benchmarking
6.30.4 Strategic Initiatives
6.31 ITClinical
6.31.1 Company Overview
6.31.2 Financial Performance
6.31.3 Product Benchmarking
6.31.4 Strategic Initiatives
Chapter 7. Methodology and Scope
7.1. Research Methodology
7.2. Research Scope & Assumption
7.3. List of Data Sources

List of Tables

1. Pharmacovigilance Market – Industry Summary & Critical Success Factors (CSFs)
2. Global Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 – 2020, Revenue (USD Million)
3. Global Pharmacovigilance Market Revenue, By Type of Service Provider , 2012 – 2020, Revenue (USD Million)
4. Global Pharmacovigilance Market Revenue, By Region, 2012 – 2020, Revenue (USD Million)
5. Pharmacovigilance Market – Key market driver analysis
6. Pharmacovigilance – Key market restraint analysis
7. North America Pharmacovigilance Market Size And Trends, 2012 – 2020, Revenue (USD Million)
8. North America Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 – 2020 (USD Million)
9. North America Pharmacovigilance Market Revenue, By Type of Service provider, 2012 – 2020 (USD Million)
10. Europe Pharmacovigilance Market Size And Trends, 2012 – 2020, Revenue (USD Million)
11. Europe Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 – 2020 (USD Million)
12. Europe Pharmacovigilance Market Revenue, By Type of service Provider, 2012 – 2020 (USD Million)
13. Asia Pacific Pharmacovigilance Market Size And Trends, 2012 – 2020, Revenue (USD Million)
14. Asia Pacific Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 – 2020 (USD Million)
15. Asia Pacific Pharmacovigilance Market Revenue, By Type of service Provider, 2012 – 2020 (USD Million)
16. RoW Pharmacovigilance Market Size And Trends, 2012 – 2020, Revenue (USD Million)
17. RoW Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 – 2020 (USD Million)
18. RoW Pharmacovigilance Market Revenue, By Type of Service Provider, 2012 – 2020 (USD Million)

List of Figures

1. Pharmacovigilance: Market Segmentation
2. Global Pharmacovigilance Market, 2012 – 2020, Revenue (USD Million)
3. Pharmacovigilance Market Dynamics
4. Key Opportunities Prioritized
5. Pharmacovigilance Market – Porter’s Analysis
6. Pharmacovigilance Market – PESTEL Analysis
7. Pharmacovigilance Company Market Share Analysis, 2013
8. Pharmacovigilance Market Share, By Clinical Trial Phase, 2013 & 2020
9. Pharmacovigilance Market Share, By Type of Service Provider, 2013 & 2020
10. Pharmacovigilance Market Share, By Region, 2013 & 2020


【レポート販売概要】

■ タイトル:医薬品の副作用調査の世界市場分析:臨床試験フェーズ別(前臨床試験、フェーズI / 1、フェーズII / 2、フェーズIII / 3、フェーズIV / 4試験)、サービス提供者別(自宅内、契約委託)、セグメント予測、-2020
■ 英文:Pharmacovigilance Market Analysis By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial), By Type Of Service Providers (In House, Contract Outsourcing) And Segment Forecasts To 2020
■ 発行日:2015年2月15日
■ 調査会社:Grand View Research
■ 商品コード:GVIEW707656
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。